Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS11
PHASE 3 / 2-33
RECRUITING4
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO20%
Delay Index: of 5 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Genrix (Shanghai) Biopharmaceutical Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| GR1802 injection NCT06315426 |
P2 | Active, not recruiting | Allergic Rhinitis | 240 | 2025-05 |
| GR1802 injection NCT07154342 |
P3 | Recruiting | Allergic Rhinitis, Seasonal | 150 | 2026-04-30 |
| GR1803 injection NCT07090954 |
P1/2 | Not yet recruiting | Multiple Myeloma | 32 | 2026-07-31 |
| GR1803 injection NCT06566547 |
P2 | Active, not recruiting | Multiple Myeloma | 116 | 2027-05-12 (+9 mo) |
| GR1802 injection NCT07199257 |
P3 | Not yet recruiting | Allergic Rhinitis, Seasonal | 144 | 2027-05-15 |
| GR1803 injection NCT07348055 |
P1/2 | Recruiting | Systemic Lupus Erthematosus; Auto Immune Disease | 44 | 2027-06-01 |
| GR1803 NCT06952075 |
P2 | Recruiting | Multiple Myleoma | 30 | 2027-07-01 |
| GREVIT-II NCT07930039 |
P2 | Not yet recruiting | Vitiligo | 120 | 2028-05 |
| GREVIT NCT07647237 |
P1/2 | Not yet recruiting | Vitiligo | 116 | 2028-06 |
| low dose GR1603 in phase Ⅰb NCT06015230 |
P1/2 | Active, not recruiting | Lupus Erythematosus, Systemic | 136 | 2028-06-10 |
| GR1803 injection NCT07452198 |
P3 | Recruiting | Multiple Myeloma | 358 | 2029-03 |